Department of Family and Community Medicine, Faculty of Medicine, University of Jeddah, Jeddah 21589, Saudi Arabia.
Department of Family and Community Medicine, College of Medicine, King Khalid University, Abha 62529, Saudi Arabia.
Medicina (Kaunas). 2022 Jul 21;58(7):972. doi: 10.3390/medicina58070972.
: Although several vaccines have been produced and administered around the world, new SARS-CoV-2 worsened the COVID-19 infection risk and impacted the initial vaccine dosage effectiveness. Based on studies indicating that the third and fourth COVID-19 vaccine doses significantly reduced COVID-19 transmission, Saudi Arabia has been administering COVID-19 booster vaccine doses to its citizens. The purpose of this study was to evaluate the uptake of the COVID-19 vaccine booster in relation to the socio-demographic characteristics and other associated factors among the Saudi population. : This study was an online analytical cross-sectional study using a self-administered questionnaire. Pearson Chi-square test and multiple logistic regression analyses were used to determine factors associated with the uptake of COVID-19 booster dose vaccines. : A total of 2332 responded to our study. Overall, 527 (22.6%) participants had received a booster dose. An age of 55 and above (aOR: 5.415; 95% CI: 2.719-10.783), Eastern region (aOR: 2.513; 95% CI: 1.566-4.033), history of influenza vaccination at annual intervals (aOR: 2.387; 95% CI: 1.730-3.293), the first dose of Moderna vaccine (aOR: 1.324; 95% CI: 1.160-1.510), and cancer (aOR: 2.161; 95% CI: 1.218-3.879) were independent factors most associated with a higher uptake of the COVID-19 vaccine booster dose. In contrast, the second dose of Moderna vaccine (aOR: 0.794; 95% CI: 0.683-0.922), AstraZeneca vaccine (aOR: 0.691; 95% CI: 0.509-0.939), strong symptoms from side effects after the second dose of the COVID-19 vaccine (aOR: 0.615; 95% CI: 0.404-0.935) were independent factors most associated with a lower uptake of the COVID-19 vaccine booster dose. : Our findings indicate low COVID-19 vaccine booster uptake. This necessitates the need for strategies to address discouraging factors of the COVID-19 vaccine booster dose uptake and engage the Saudi population to raise awareness about the importance of the booster dose.
尽管已经在全球范围内生产和使用了几种疫苗，但新型 SARS-CoV-2 加剧了 COVID-19 感染风险，并影响了初始疫苗剂量的有效性。基于研究表明，第三和第四剂 COVID-19 疫苗显著降低了 COVID-19 的传播，沙特阿拉伯已向其公民提供 COVID-19 加强疫苗接种。本研究旨在评估与沙特人口的社会人口特征和其他相关因素相关的 COVID-19 疫苗加强针的接种情况。
本研究是一项在线分析性横断面研究，使用自我管理的问卷。采用 Pearson Chi-square 检验和多因素逻辑回归分析来确定与 COVID-19 加强剂量疫苗接种相关的因素。
共有 2332 人回应了我们的研究。总体而言，有 527 名（22.6%）参与者接受了加强剂量。年龄在 55 岁及以上（优势比：5.415；95%置信区间：2.719-10.783），东部地区（优势比：2.513；95%置信区间：1.566-4.033），每年接种流感疫苗（优势比：2.387；95%置信区间：1.730-3.293），首次接种 Moderna 疫苗（优势比：1.324；95%置信区间：1.160-1.510）和癌症（优势比：2.161；95%置信区间：1.218-3.879）是与 COVID-19 疫苗加强剂量接种率较高相关的最重要的独立因素。相比之下，接种第二剂 Moderna 疫苗（优势比：0.794；95%置信区间：0.683-0.922）、阿斯利康疫苗（优势比：0.691；95%置信区间：0.509-0.939）、第二剂 COVID-19 疫苗后出现严重副作用（优势比：0.615；95%置信区间：0.404-0.935）是与 COVID-19 疫苗加强剂量接种率较低相关的最重要的独立因素。
我们的研究结果表明 COVID-19 疫苗加强针的接种率较低。这就需要制定策略来解决 COVID-19 疫苗加强剂量接种的阻碍因素，并让沙特民众提高对加强剂量的认识。
